Business Description
Sunshine Biopharma Inc
NAICS : 325412
SIC : 2834
Share Class Description:
SBFMW: Warrants (15/02/2027)Total Employee Number:
50Description
Sunshine Biopharma Inc is a pharmaceutical company offering and researching life-saving medicines in a wide variety of therapeutic areas, including oncology and antivirals. Through its subsidiaries, the company has various generic prescription drugs on the market in Canada and is also involved in developing and selling OTC supplements. In addition, the company is conducting a proprietary drug development program, which is comprised of K1.1 mRNA targeted for liver cancer and SBFM-PL4, PLpro protease inhibitor for SARS Coronavirus infections.
Financial Strength
6/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Cash-To-Debt | 20.25 | |||||
Equity-to-Asset | 0.82 | |||||
Debt-to-Equity | 0.03 | |||||
Debt-to-EBITDA | -0.13 | |||||
Interest Coverage | N/A |
N/A
|
N/A
| |||
Piotroski F-Score | 4/9 | |||||
Altman Z-Score | -1.41 | |||||
Beneish M-Score | -2.43 | |||||
WACC vs ROIC | ||||||
Growth Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year Revenue Growth Rate | -72.8 | |||||
3-Year EBITDA Growth Rate | 92 | |||||
3-Year EPS without NRI Growth Rate | 89.9 | |||||
3-Year FCF Growth Rate | 86.1 | |||||
3-Year Book Growth Rate | -87.1 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Current Ratio | 5.46 | |||||
Quick Ratio | 3.3 | |||||
Cash Ratio | 2.45 | |||||
Days Inventory | 195.11 | |||||
Days Sales Outstanding | 39.76 | |||||
Days Payable | 78.69 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year Average Share Buyback Ratio | -688.9 | |||||
Shareholder Yield % | 1.6 |
Profitability Rank
1/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Gross Margin % | 30.3 | |||||
Operating Margin % | -14.71 | |||||
Net Margin % | -16.5 | |||||
EBITDA Margin % | -15.31 | |||||
ROE % | -23.91 | |||||
ROA % | -18.8 | |||||
ROIC % | -33.94 | |||||
3-Year ROIIC % | 33.1 | |||||
ROC (Joel Greenblatt) % | -43.5 | |||||
ROCE % | -23.07 | |||||
Moat Score | 2 | |||||
Tariff Resilience Score | 5 |
GF Value Rank
2/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
PS Ratio | 0.02 | |||||
PB Ratio | 0.1 | |||||
EV-to-EBIT | 1.5 | |||||
EV-to-EBITDA | 1.6 | |||||
EV-to-Revenue | -0.24 | |||||
EV-to-FCF | 1.56 | |||||
Earnings Yield (Greenblatt) % | 66.67 | |||||
FCF Yield % | -125.27 |
Operating Revenue by Business Segment
Operating Revenue by Geographic Region
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsGurus Latest Trades with NAS:SBFMW
You need a Premium membership or above to view this section.
Take a 7-Day Free Trial
No Available Data
Peter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
Sunshine Biopharma Inc Executives
DetailsGF Valueâ„¢
Analyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil $) | |||
| EPS (TTM) ($) | - | ||
| Beta | - | ||
| 3-Year Sharpe Ratio | - | ||
| 3-Year Sortino Ratio | - | ||
| Volatility % | - | ||
| 14-Day RSI | 8.13 | ||
| 14-Day ATR ($) | 0.000007 | ||
| 20-Day SMA ($) | 0.0851 | ||
| 12-1 Month Momentum % | - | ||
| 52-Week Range ($) | 0.0851 - 0.0998 | ||
| Shares Outstanding (Mil) |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 4 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Sunshine Biopharma Inc Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Sunshine Biopharma Inc Stock Events
| Event | Date | Price ($) | ||
|---|---|---|---|---|
| General meeting for 2026 | 2026-12-11 10:00 | In 94 days | ||
| Third quarter earnings results for 2026 | 2026-11-13 | In 65 days | ||
| Second quarter earnings results for 2026 | 2026-08-12 | 0.09 (+0.00%) | ||
| First quarter earnings results for 2026 | 2026-05-13 | 0.09 (+0.00%) | ||
| Annual report for 2025 | 2026-04-03 | 0.09 (+0.00%) | ||
| General meeting for 2025 | 2025-12-11 10:00 | -- | ||
| Third quarter earnings results for 2025 | 2025-11-13 | -- | ||
| Second quarter earnings results for 2025 | 2025-08-12 | -- | ||
| First quarter earnings results for 2025 | 2025-05-15 | -- | ||
| Annual report for 2024 | 2025-04-01 | -- |
Show
Entries
Sunshine Biopharma Inc Frequently Asked Questions
What is Sunshine Biopharma Inc(SBFMW)'s stock price today?
The current price of SBFMW is $0.09. The 52 week high of SBFMW is $0.10 and 52 week low is $0.09.
When is next earnings date of Sunshine Biopharma Inc(SBFMW)?
The next earnings date of Sunshine Biopharma Inc(SBFMW) is 2026-11-13 Est..
Does Sunshine Biopharma Inc(SBFMW) pay dividends? If so, how much?
Sunshine Biopharma Inc(SBFMW) does not pay dividend.
Press Release
Articles on Sunshine Biopharma Inc
No articles.
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers